Branch Retinal vein occlusion
Conditions
Interventions
Traditional preventive laser group:3+PRN(lucentis)+preventive laser
Precision laser group:3+PRN(lucentis)+on-demanded laser
Sponsors
Eye and ENT hospital of Fudan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with ischemic BRVO secondary to macular edema involving the fovea (<6 months).
Exclusion criteria
Exclusion criteria: (1) Any eye has active eye or eye inflammation (for example: blepharitis, infectious conjunctivitis, keratitis, scleritis, uveitis, endophthalmitis, etc.); (2) There are macular diseases that the investigator thinks may affect the recovery of vision, such as macular epithelium, vitreoretinal traction, macular atrophy, etc.; (3) Treat other diseases of the eye that have caused macular edema in the past, such as wet AMD, diabetic retinopathy, uveitis or other intraocular inflammation, etc.; (4) Treatment of obvious cataract in the side eye. Researchers believe that cataract surgery is needed in the next 12 months; (5) Treatment of any macular edema before treatment of the eye, including: intravitreal injection of corticosteroids, any anti-VEGF drug treatment; (6) The treatment eye has active retina and/or iris neovascularization; (7) Past or present uncontrollable glaucoma in any eye (the intraocular pressure is still > 30mmHg after anti-glaucoma treatment, or has received glaucoma filtering surgery); (8) Patients with type I or type II diabetes; (9) There is a history of systemic use of anti-VEGF drug therapy within 6 months before screening; (10) Patients with severe asthma, history of allergies or systemic diseases who cannot accept FFA examination or intraocular injection of ranibizumab; (11) Patients with poor blood pressure control (defined as systolic blood pressure still>= 160mmHg or diastolic blood pressure >= 90mmHg after treatment with antihypertensive drugs); (12) Patients with severe cardiovascular and cerebrovascular diseases such as myocardial infarction, cerebral infarction, active diffuse intravascular coagulation and obvious bleeding tendency within 6 months before screening; (13) Patients with confirmed systemic immune diseases that require treatment; (14) Are participating in or have participated in other relevant clinical trial treatments within the last 6 months; (15) Those who refuse or cannot follow up on time due to various reasons; (16) Women of childbearing age who have not used effective contraceptive measures, pregnant and lactating women; (17) Active mental disorders or other mental disorders that affect the patient's ability to sign informed consent and understand; (18) Those who refuse to sign informed consent; (18) Researchers think that need to be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| best corrected visual acuity;central macular thickness; | — |
Countries
China
Contacts
Public ContactLiu Wei
Eye and ENT hospital of Fudan University
Outcome results
None listed